Navigation Links
Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
Date:7/17/2009

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3 clinical trials in the Contrave program on Monday, July 20, 2009 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time.

Orexigen management will host the call and webcast to discuss the results of these clinical trials and answer questions. The live call may be accessed by phone by calling 1-800-561-2813 (domestic) or 617-614-3529 (international), participant code 14007929. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM) which is in the later stages of Phase II development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com.

<
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "MEMS Gyroscopes Analog Devices ADIS16136 ... report to their offering. ... tactical grade applications made a lot of progress ... reliability. They are now accepted in high-reliability environments, ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) has announced ... Filters - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena Cava (IVC) ... 2016. The North America accounts ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... BerGenBio AS, a biopharmaceutical company ... cancers, today announces that it has raised NOK90 million ... and existing investors. BerGenBio will use the ... its pipeline of innovative cancer therapeutics, in particular an ... BGB324, a first-in-class selective Axl kinase inhibitor, which is ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2
... Aug. 17 Luminex Corporation (Nasdaq: LMNX ... it has donated the first commercial unit of its ... his scientific team at the Papua New Guinea Institute ... in Papua New Guinea to progress malaria research led ...
... Equinox Surgical Solutions LLC today announced ... designed and developed by a minimally invasive, Board Certified, ... and his team to improve patient and surgical team ... acquire, hand-off, dispose of and reload sutures with an ...
Cached Medicine Technology:Luminex Donates Company's First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research 2Luminex Donates Company's First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research 3Equinox Surgical Solutions Launches Flagship Product, SutureAssist® 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Ecosystem Assessment, scientists have said that degradation of the eco ... human health and may cause greater harm in next 50 ... to cause a major outbreak and new diseases are emerging ... system are being used in unsustainable way. ,The report ...
... and 799 non-diabetic women volunteers in the age group ... Center, Seattle, US had said that being diabetic increases ... women who have had their menopause. ,The researchers ... hemoglobin A1c, urine culture, residual bladder volume and diabetes ...
... into a data comprising of 5461 girls between 11 to ... makes these girls more prone to stress fractures. ,The ... vigorous physical activity, which often lasts for 16 or more ... risk of having a stress fracture than the girls doing ...
... that tumor necrosis factor (TNF)-á-blocking therapy used for ... ,The study done by the Dutch scientists ... Netherlands had taken into account the number and ... with the TNF-á-blocking therapy. 128 dermatological conditions in ...
... of University of Mississippi Medical Center US have found ... hypertension and high blood pressure. ,3216 people who ... subjected to 24 hr monitoring of systolic and diastolic ... to mean daytime and nighttime systolic and diastolic blood ...
... rats suggests that eating onions may be the key to ... have identified a compound in onions, a peptide called GPCS ... involved segregation of bone cells of newborn mice that were ... These cells were later exposed to the peptide GPCS. The ...
Cached Medicine News:
Designed for use in traditional external approach DCRs in pediatric patients & for endoscopic DCRs in adults or children. Lumen 6.0mm long, ID-1.4mm (.12 in); OD-5.0mm (.20 in), Outer flanges 8.0mm ...
...
Universal, clear, lightweight plastic with smooth edges & ventilation holes for patient comfort...
... BP monitor is designed to automatically measure ... BP along with heart rate. It's a ... in treadmill, ergometer and pharmacological stress test ... in research environments., ,Tango excels where ...
Medicine Products: